| Study name |
SeMoRa‐3 study. Self‐monitoring in rheumatoid arthritis |
| Methods |
Randomised parallel trial. The Netherlands |
| Participants |
Inclusion criteria: Adults who own a smartphone, diagnosed with rheumatoid arthritis by a rheumatologist for >=2 years, with low disease activity and taking a disease‐modifying anti‐rheumatic drug |
| Interventions |
Patients allocated to the intervention group will have access to the MyRheumatism application, which collects weekly self‐assessed questionnaire data (up to three reminders). Data will be transmitted through secure servers to the electronic medical record, where it will be revised by healthcare professionals. |
| Outcomes |
Main outcomes: disease activity, number of outpatient clinic visits |
| Starting date |
1 June 2019 |
| Contact information |
Bart Seppen. Email: b.seppen@reade.nl |
| Notes |
Trial registry NL7715 |
